Plain-English translation of NCT06342713 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This was the first study in humans of a new medication called , designed to treat autoimmune skin diseases. Researchers tested the medication in healthy volunteers first to understand how safe it was and how the body processed it, then studied it in people living with atopic dermatitis and prurigo nodularis to see if the treatment helped reduce symptoms.
Autoimmune skin diseases like atopic dermatitis and prurigo nodularis cause severe itching and discomfort and are often hard to treat with existing options. This trial aimed to find out whether this new medication could offer patients a safer and more effective way to manage these painful conditions.
Depending on which part of the study you joined, you would either receive a single dose or multiple doses of the medication over 2 weeks (for healthy volunteers) or up to 12 weeks (for patients with skin disease), with regular visits for blood tests, physical exams, and assessments of how your skin responded. The entire trial lasted up to 24 months, with a final safety check 30 days after your last dose.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Australia
China